Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#191 / 200 Total
PDYN - Palladyne AI Corp. - Stock Price Chart
TickerPDYN [NASD]
CompanyPalladyne AI Corp.
CountryUSA
IndustrySoftware - Infrastructure
Market Cap39.11MEPS (ttm)-3.80
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S6.36EPS next 5Y-
P/B0.96EPS Q/Q61.31%
Dividend-Sales Q/Q-87.81%
Insider Own46.89%Inst Own10.92%
Insider Trans0.00%Inst Trans200.77%
Short Float5.97%EarningsNov 14/a
Analyst Recom3.00Target Price1.00
Avg Volume1.01M52W Range0.40 - 3.25
Apr-16-24 07:52AM PDYN Stock Earnings: Palladyne AI Misses EPS, Misses Revenue for Q2 2023 (InvestorPlace) -8.47%
Apr-08-24 09:00AM Palladyne AI Ticker Symbol now PDYN (Business Wire) +6.91%
Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its mobile robotic systems include the Guardian S, Guardian GT, Guardian XO, and Guardian XT. The company was founded in 2015 and is headquartered in Salt Lake City, UT.
INDP - Indaptus Therapeutics Inc - Stock Price Chart
TickerINDP [NASD]
CompanyIndaptus Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap20.07MEPS (ttm)-1.84
P/E-EPS this Y-6.83%
Forward P/E-EPS next Y27.37%
PEG-EPS past 5Y56.03%
P/S-EPS next 5Y-
P/B1.63EPS Q/Q-7.83%
Dividend-Sales Q/Q-
Insider Own30.87%Inst Own7.05%
Insider Trans0.00%Inst Trans12.62%
Short Float1.70%EarningsMar 13/b
Analyst Recom1.00Target Price10.00
Avg Volume85.90K52W Range1.56 - 4.08
Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anderson Glen R.10% OwnerAug 14 '23Buy2.3423,93456,0061,190,400Aug 16 06:01 PM
Anderson Glen R.10% OwnerAug 11 '23Buy2.1235,06474,3361,166,466Aug 16 06:01 PM
Anderson Glen R.10% OwnerAug 10 '23Buy1.9444,35486,0471,131,402Aug 16 06:01 PM
HITI - High Tide Inc. - Stock Price Chart
TickerHITI [NASD]
CompanyHigh Tide Inc.
CountryCanada
IndustryPharmaceutical Retailers
Market Cap152.11MEPS (ttm)-0.35
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-7.01%
P/S0.41EPS next 5Y-
P/B1.54EPS Q/Q92.08%
Dividend-Sales Q/Q8.16%
Insider Own9.69%Inst Own8.30%
Insider Trans0.00%Inst Trans-
Short Float4.59%EarningsMar 15/a
Analyst Recom-Target Price-
Avg Volume579.77K52W Range1.14 - 2.85
High Tide, Inc. is a retail-focused cannabis company, which engages in the manufacture and distribution of consumption accessories. It operates through the following segments: Retail, Wholesale, and Corporate. Its brands are Canna Cabana, Fastendr, Grasscity, Smoke Cartel, Daily High Club, DankStop, NuLeaf Naturals, FAB CBD, Blessed CBD, Valiant Distribution, and Famous Brandz. The company was founded by Harkirat Grover in 2009 and is headquartered in Calgary, Canada.
BCTX - BriaCell Therapeutics Corp - Stock Price Chart
TickerBCTX [NASD]
CompanyBriaCell Therapeutics Corp
CountryCanada
IndustryBiotechnology
Market Cap35.00MEPS (ttm)-1.67
P/E-EPS this Y-6.92%
Forward P/E-EPS next Y-0.72%
PEG-EPS past 5Y32.71%
P/S-EPS next 5Y-
P/B-EPS Q/Q7.71%
Dividend-Sales Q/Q-
Insider Own12.15%Inst Own15.45%
Insider Trans0.00%Inst Trans-
Short Float4.83%EarningsMar 19/b
Analyst Recom1.00Target Price18.00
Avg Volume84.78K52W Range2.01 - 7.59
Apr-24-24 08:00AM BriaCell Announces Oral and Poster Presentations at ASCO 2024 (GlobeNewswire) -5.60%
Apr-10-24 08:00AM BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+ and Bria-PROS+ Clinical Candidates for Breast and Prostate Cancer (GlobeNewswire)
Apr-09-24 08:00AM BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR (GlobeNewswire)
Mar-19-24 06:52AM BCTX Stock Earnings: BriaCell Therapeutics Reported Results for Q2 2024 (InvestorPlace) -6.55%
Mar-07-24 08:00AM BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies (GlobeNewswire) -7.05%
Mar-06-24 08:00AM BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference (GlobeNewswire) -8.24%
Feb-27-24 08:00AM BriaCell Provides Update on Alleged Illegal Trading of Public Securities (GlobeNewswire)
Feb-07-24 08:00AM BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case (GlobeNewswire)
Feb-06-24 08:30AM Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing (GlobeNewswire) +5.34%
Jan-30-24 10:48PM BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting (GlobeNewswire)
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company, which engages in the development of immunotherapies for the treatment of cancer. Its technologies include Bria-IMT and Bria-OTS. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.
OCGN - Ocugen Inc - Stock Price Chart
TickerOCGN [NASD]
CompanyOcugen Inc
CountryUSA
IndustryBiotechnology
Market Cap303.64MEPS (ttm)-0.27
P/E-EPS this Y5.95%
Forward P/E-EPS next Y-0.63%
PEG-EPS past 5Y41.20%
P/S215.35EPS next 5Y-
P/B7.46EPS Q/Q57.07%
Dividend-Sales Q/Q-
Insider Own2.20%Inst Own10.20%
Insider Trans0.00%Inst Trans-2.91%
Short Float17.28%EarningsApr 02/b
Analyst Recom1.00Target Price6.67
Avg Volume9.13M52W Range0.34 - 2.11
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zhang JungeDirectorJun 14 '23Buy0.50200,27899,9991,077,182Jun 16 04:22 PM
OPFI - OppFi Inc - Stock Price Chart
TickerOPFI [NYSE, RUT]
CompanyOppFi Inc
CountryUSA
IndustryCredit Services
Market Cap318.34MEPS (ttm)-0.03
P/E-EPS this Y8.50%
Forward P/E4.45EPS next Y16.57%
PEG-EPS past 5Y-
P/S1.17EPS next 5Y-
P/B30.44EPS Q/Q-40.68%
Dividend-Sales Q/Q35.70%
Insider Own84.42%Inst Own6.27%
Insider Trans-0.02%Inst Trans1.08%
Short Float6.90%EarningsMar 07/a
Analyst Recom1.00Target Price5.50
Avg Volume337.25K52W Range1.74 - 5.12
OppFi, Inc. is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It supports consumers, who are turned away by mainstream options, to build better financial health, through transparency, responsible lending, financial inclusion, and an excellent customer experience. The company was founded by Todd G. Schwartz and Theodore Schwartz in 2012 and is headquartered in Chicago, IL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McKay Christopher J.Chief Risk & Analytics OfficerApr 15 '24Option Exercise0.003,8500181,293Apr 17 05:42 PM
Johnson Pamela D.CFOApr 15 '24Option Exercise0.001,0410138,161Apr 17 05:44 PM
Johnson Pamela D.CFOJan 22 '24Option Exercise0.001,041030,283Jan 24 04:26 PM
McKay Christopher J.Chief Risk & Analytics OfficerJan 22 '24Option Exercise0.003,851049,633Jan 24 04:27 PM
Johnson Pamela D.CFONov 22 '23Option Exercise0.001,041029,820Nov 27 08:55 PM
ENPH - Enphase Energy Inc - Stock Price Chart
TickerENPH [NASD, S&P 500]
CompanyEnphase Energy Inc
CountryUSA
IndustrySolar
Market Cap14.55BEPS (ttm)1.93
P/E55.53EPS this Y-33.58%
Forward P/E20.87EPS next Y75.29%
PEG3.75EPS past 5Y-
P/S7.96EPS next 5Y14.80%
P/B15.79EPS Q/Q-111.65%
Dividend-Sales Q/Q-63.73%
Insider Own3.98%Inst Own75.53%
Insider Trans-0.54%Inst Trans8.30%
Short Float7.81%EarningsApr 23/a
Analyst Recom2.17Target Price126.57
Avg Volume4.06M52W Range73.49 - 228.36
Apr-24-24Downgrade Guggenheim Neutral → Sell $92
Apr-24-24Downgrade Jefferies Buy → Hold $135 → $111
Apr-24-24Reiterated TD Cowen Buy $140 → $145
Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RANHOFF DAVID AEVP & Chief Commercial OfficerApr 15 '24Sale116.295,000581,474119,948Apr 16 06:53 PM
GOMO STEVEN JDirectorApr 04 '24Option Exercise0.7045,66831,968138,773Apr 05 07:29 PM
RANHOFF DAVID AEVP & Chief Commercial OfficerMar 15 '24Sale108.895,000544,425124,948Mar 15 07:13 PM
Kothandaraman BadrinarayananPresident & CEOFeb 27 '24Buy120.544,000482,1541,655,171Feb 28 06:16 PM
Kothandaraman BadrinarayananPresident & CEOFeb 09 '24Option Exercise1.29557,660719,3811,947,810Feb 12 05:53 PM
SLS - SELLAS Life Sciences Group Inc - Stock Price Chart
TickerSLS [NASD]
CompanySELLAS Life Sciences Group Inc
CountryUSA
IndustryBiotechnology
Market Cap86.66MEPS (ttm)-1.36
P/E-EPS this Y14.93%
Forward P/E-EPS next Y11.40%
PEG-EPS past 5Y61.44%
P/S-EPS next 5Y-
P/B-EPS Q/Q41.66%
Dividend-Sales Q/Q-
Insider Own0.69%Inst Own9.93%
Insider Trans0.00%Inst Trans-11.88%
Short Float9.43%EarningsMar 28/a
Analyst Recom1.00Target Price5.75
Avg Volume1.45M52W Range0.50 - 1.91
Mar-28-24 10:54PM SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q4 2023 (InvestorPlace)
04:05PM SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
07:00AM GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA (zanubrutinib) Treating Diffuse Large B Cell Lymphoma (PR Newswire)
Mar-26-24 07:35AM SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study (GlobeNewswire)
Mar-19-24 04:05PM SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
08:47AM SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET (GlobeNewswire)
Mar-15-24 09:00AM SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -29.03%
Mar-08-24 08:00AM SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships (GlobeNewswire)
Mar-01-24 08:30AM SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference (GlobeNewswire)
Feb-29-24 08:00AM SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time (GlobeNewswire)
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.
KSPI - Kaspi.kz JSC ADR - Stock Price Chart
TickerKSPI [NASD]
CompanyKaspi.kz JSC ADR
CountryKazakhstan
IndustrySoftware - Infrastructure
Market Cap22.31BEPS (ttm)9.59
P/E12.12EPS this Y24.14%
Forward P/E7.65EPS next Y25.35%
PEG-EPS past 5Y37.75%
P/S5.33EPS next 5Y-
P/B9.30EPS Q/Q31.92%
Dividend7.17%Sales Q/Q41.43%
Insider Own0.00%Inst Own11.03%
Insider Trans-Inst Trans-
Short Float0.51%EarningsApr 22/b
Analyst Recom1.00Target Price138.31
Avg Volume365.03K52W Range78.00 - 136.17
Kaspi.kz JSC provides a mobile app. The firm operates through the following segments: Payments Platform, Marketplace Platform and Fintech Platform. The Payments Platform segment consists of both consumers and merchants, to facilitate cashless, digital transactions. The Marketplace platform segment connects merchants and consumers enabling merchants to increase their sales and consumers to buy a broad selection of products and services offered by a variety of merchants. The Fintech Platform segment enables customers to manage their personal finances online and access consumer finance and deposit products primarily through the Kaspi.kz Super App. The company was founded by Mikheil Nugzarovich Lomtadze and Vyacheslav Konstantinovich Kim on October 16, 2008 and is headquartered in Almaty, Kazakhstan.
LGVN - Longeveron Inc - Stock Price Chart
TickerLGVN [NASD]
CompanyLongeveron Inc
CountryUSA
IndustryBiotechnology
Market Cap5.59MEPS (ttm)-5.83
P/E-EPS this Y31.37%
Forward P/E-EPS next Y-217.14%
PEG-EPS past 5Y-25.24%
P/S7.87EPS next 5Y-
P/B0.63EPS Q/Q-1103.63%
Dividend-Sales Q/Q-47.93%
Insider Own69.95%Inst Own7.75%
Insider Trans16.55%Inst Trans-
Short Float2.86%EarningsFeb 27/a
Analyst Recom1.00Target Price30.05
Avg Volume2.07M52W Range1.62 - 44.00
Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hare JoshuaChief Scientific OfficerApr 11 '24Buy2.3542,553100,000633,280Apr 12 07:00 PM
Soffer RockDirectorApr 11 '24Buy2.3531,91575,000208,534Apr 12 07:00 PM
Hashad Mohamed Wa'el AhmedChief Executive OfficerApr 11 '24Buy2.3510,63824,99919,616Apr 12 07:00 PM
Hare JoshuaChief Scientific OfficerApr 10 '24Buy2.35106,383250,000590,727Apr 12 07:00 PM
Soffer RockDirectorApr 10 '24Buy2.35106,383250,000176,619Apr 12 07:00 PM
110151617181920